GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Anixa Biosciences ANIX · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.16

-0.63%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−$10.9m

FY2016FY2025

Free cash flow

−$7.2m

FY2016FY2025

Shareholders' equity

$15.2m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue——$210,000$2.47bn$512,000—$250,000$1.1m$362,500$300,000
Research and development$5.1m$6.4m$4.8m$6.7m$6.2m$4.4m$5.5m$6.8m$1.6m$1.6m
Operating income−$11.7m−$13.8m−$11.0m−$13.9m−$13.1m−$10.0m−$11.9m−$13.7m−$6.1m−$4.5m
Net income−$10.9m−$12.6m−$9.8m−$13.6m−$12.9m−$10.1m−$11.6m−$14.0m−$5.0m−$5.0m
Diluted earnings per share-0.34-0.39-0.32-0.44-0.43-0.40-0.56-0.73-0.30-0.52

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$16.1m$21.6m$25.5m$30.4m$36.3m$9.5m$6.3m$6.4m$8.8m$5.6m
Cash and short-term investments$15.2m$19.9m$23.8m$29.7m$35.7m$9.1m$5.8m$5.1m$6.8m$3.2m
Total liabilities$2.1m$2.7m$2.2m$2.2m$1.5m$1.2m$1.5m$1.3m$889,493$4.6m
Debt$204,000$232,000$175,000$221,000$259,000$55,198———$4.2m
Shareholders' equity$15.2m$20.0m$24.3m$29.0m$35.4m$8.8m$5.2m$5.4m$7.9m$987,475
Shares outstanding32m32m31m31m30m25m21m19m17m10m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$7.2m−$7.3m−$6.2m−$6.5m−$4.9m−$6.2m−$4.7m−$4.3m−$3.8m−$3.4m
Capital spending—————−$15,791−$175,457−$38,404−$30,188−$146,521
Free cash flow−$7.2m−$7.3m−$6.2m−$6.5m−$4.9m−$6.2m−$4.9m−$4.3m−$3.8m−$3.5m

Latest quarters

By quarter end

Jul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Operating income−$2.7m−$2.6m−$2.7m−$2.9m−$2.4m−$3.0m−$3.4m−$3.2m
Net income−$2.6m−$2.6m−$2.6m−$2.7m−$2.3m−$2.8m−$3.2m−$2.9m
Diluted earnings per share-0.08-0.07-0.08-0.08-0.07-0.09-0.10-0.09
Cash from operations−$1.0m−$1.0m−$2.0m−$1.0m−$1.0m−$1.0m−$2.0m—
Total assets$15.1m$14.9m$15.2m$16.1m$17.7m$17.0m$18.9m$21.6m
Cash and short-term investments$13.9m$13.7m$14.2m$15.2m$16.0m$15.6m$17.3m$19.9m
Debt$46,000$44,000$42,000$41,000$39,000$37,000$36,000$29,000
Shareholders' equity$14.5m$14.5m$15.1m$15.2m$16.6m$16.1m$17.9m$20.0m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-5.5%3.2%28.6%
Net income-7.0%1.5%23.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-9.3-5.9-12.3-9.6-6.9-7.6-5.8-5.4-7.8-6.5
Price to sales———0.1174.8—271.667.9108.1108.7

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return28%-35%-1%28%12%-1%-19%35%-28%84%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 25-to-1 reverse split · 26 Jun 2015
  • 2-for-1 split · 18 Jun 1996
  • 2-for-1 split · 19 Mar 1991

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.